drugset
drugset / Trial / NCT07513129

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

NCT07513129 ↗

Phase 1 Recruiting 18 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single institution, Phase 1 study of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult participants with relapsed or refractory T-ALL or T-LBL

Timeline

Start
2026-06-05
Primary completion
2029-12-31
Completion
2031-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Subcutaneous
Subject Daratumumab Monoclonal antibody — Intravenous
Subject Dexamethasone Small molecule — Oral
Subject Venetoclax Small molecule — Oral

Indications

T-cell acute lymphoblastic leukemia